Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

~9 mi. (Gdynia, Poland, +158 more cities)

Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 2400)

Non-Small Cell Lung Carcinoma

olaparib, +4 more drugs

chemotherapy, +3 more types

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

~9 mi. (Gdynia, Poland, +150 more cities)

Szpitale Pomorskie Sp. z o.o. ( Site 0935)

Head and Neck Squamous Cell Carcinoma

cisplatin, +2 more drugs

chemotherapy, +2 more types

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)

~9 mi. (Gdynia, Poland, +127 more cities)

Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 2504)

Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions

lenvatinib, +1 more drug

immunotherapy, +1 more type

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

~9 mi. (Gdynia, Poland, +44 more cities)

Szpitale pomorskie gdynia dept of haematology

BCL2 Fusion, +2 more biomarkers

Diffuse Large B-Cell Lymphoma, +3 more conditions

cisplatin, +5 more drugs

chemotherapy, +3 more types

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

~25 mi. (Gdańsk, Poland, +199 more cities)

Copernicus PL Sp. z o.o. ( Site 0603)

Hepatocellular Carcinoma

pembrolizumab

immunotherapy

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

~25 mi. (Gdańsk, Poland, +356 more cities)

Uniwersyteckie Centrum Kliniczne

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

~25 mi. (Gdańsk, Poland, +137 more cities)

Uniwersyteckie Centrum Kliniczne-Klinka Chirurgii Onkologicznej ( Site 0960)

Skin Squamous Cell Carcinoma

pembrolizumab

immunotherapy

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

~25 mi. (Gdańsk, Poland, +201 more cities)

Uniwersyteckie Centrum Kliniczne /ID# 222069

Myelodysplastic Syndromes

azacitidine, +1 more drug

chemotherapy

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

~25 mi. (Gdańsk, Poland, +189 more cities)

Uniwersyteckie Centrum Kliniczne /ID# 221298

del(11)(q10), +27 more biomarkers

Myelofibrosis Transformation in Essential Thrombocythemia, +2 more conditions

navitoclax, +1 more drug

targeted therapy

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

~25 mi. (Gdańsk, Poland, +85 more cities)

Investigational Site Number :6160008

Smoldering Plasma Cell Myeloma

dexamethasone, +2 more drugs

chemotherapy, +2 more types

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)

~25 mi. (Gdańsk, Poland, +32 more cities)

Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 1103)

ER Negative, +2 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +12 more conditions

cisplatin, +4 more drugs

chemotherapy, +2 more types

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

~25 mi. (Gdańsk, Poland, +115 more cities)

Uniwersyteckie Centrum Kliniczne ( Site 1809)

ATM Loss, +27 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib, +1 more drug

immunotherapy, +1 more type